Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
Public ClinicalTrials.gov record NCT00014339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Enzyme products such as Wobe-Mugos E may help to reduce the side effects of multiple myeloma therapy. It is not yet known if chemotherapy is more effective with or without Wobe-Mugos E in treating multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or without Wobe-Mugos E in treating patients who have stage II or stage III multiple myeloma.
Study identification
- NCT ID
- NCT00014339
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Wobe-Mugos E Drug
- melphalan Drug
- prednisone Drug
- quality-of-life assessment Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2000
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 17, 2013
Started 2000
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southwest Clinical Research, Incorporated | Phoenix | Arizona | 85032 | — |
| Arizona Clinical Research Center | Tucson | Arizona | 85712 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Providence Saint Joseph Medical Center - Burbank | Burbank | California | 91505 | — |
| Comprehensive Cancer Centers of the Desert | Palm Springs | California | 92262 | — |
| Southwest Cancer Care | Poway | California | 92064 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Oncology Radiation Associates | Miami | Florida | 33133 | — |
| Cancer Care Specialists of Central Illinois, S.C. | Decatur | Illinois | 62526 | — |
| Indiana Community Cancer Care, Inc. | Indianapolis | Indiana | 46202 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074 | — |
| Oncology-Hematology Associates, P.A. | Clinton | Maryland | 20735 | — |
| Oncology Hematology Associates of Kansas City | Kansas City | Missouri | 64131 | — |
| HemOnCare, P.C. | Brooklyn | New York | 11235 | — |
| Medcenter One Health System | Bismarck | North Dakota | 58501 | — |
| Mid Dakota Clinic, P.C. | Bismarck | North Dakota | 58501 | — |
| West Clinic, P.C. | Memphis | Tennessee | 38117 | — |
| Hematology Oncology Northwest, P.C. | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00014339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2013 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00014339 live on ClinicalTrials.gov.